Zelnorm constipation indication goes to advisory committee
FDA's Gastrointestinal Drugs Advisory Committee will consider Novartis sNDA for use of Zelnorm in the treatment of chronic constipation at its July 14 meeting. Novartis submitted the chronic constipation sNDA on Oct. 21, 2003, giving the application a 10-month user fee deadline of Aug. 21. The meeting will take place in CDER's advisory committee conference room at 5630 Fishers Lane in Rockville, Md., beginning at 8:30 a.m. [To watch a 1webcast or order a video/DVD of this meeting, go to FDAAdvisoryCommittee.com]...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."